{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-003067","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2024-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.759742+00:00","generated_at":"2026-06-06T10:02:29.223354+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GRI Bio prices $5.5M public offering of common stock and warrants at $1.10/unit","bullets":["Priced offering of 5,000,000 shares (or pre-funded warrants) at $1.10 per share, raising $5.5M gross proceeds.","Issued Series B-1 warrants (5-yr, $1.10 exercise) and Series B-2 warrants (18-mo, $1.10) for up to 10M additional shares.","Closing expected February 6, 2024; proceeds for working capital and general corporate purposes.","A.G.P./Alliance Global Partners acted as sole placement agent with 7% fee plus expense allowance.","Lock-up agreements from officers and directors for 90 days post-closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-003067","json":"https://secwatch.observer/filing/0001628280-24-003067.json","markdown":"https://secwatch.observer/filing/0001628280-24-003067.md","text":"https://secwatch.observer/filing/0001628280-24-003067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000162828024003067/0001628280-24-003067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000162828024003067/val-20240201.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T10:02:29.223354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"444377d364130ca9f2e583c791e71d7cdafa1f69","claim":"GRI Bio, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at cash fee equal to 7.0% of the gross proceeds (effective 2024-02-01).","evidence_excerpt":"On February 1, 2024, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), pursuant to which A.G.P. agreed to act as exclusive placement agent for the issuance and sale of the Shares and Warrants.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000162828024003067/0001628280-24-003067-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Value","value":"cash fee equal to 7.0% of the gross proceeds"},{"label":"Effective","value":"2024-02-01"}],"fact_type":"material_agreement"},{"claim_id":"78760391abc80f16fad825e1a70723de15b1d68b","claim":"GRI Bio, Inc. entered into Securities Purchase Agreement with each purchaser identified on the signature pages thereto valued at combined purchase price of $1.10 (effective 2024-02-01).","evidence_excerpt":"On February 1, 2024, GRI Bio, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement with each purchaser identified on the signature pages thereto (the “Purchase Agreement”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”), (i) 330,450 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) 4,669,550 pre-funded warrants (the “Pre-Funded Warrants”) exercisable for an aggregate of 4,669,550 shares of Common Stock, (iii) 5,000,000 Series B-1 common warrants (the “Series B-1 Common Warrants”) exercisable for an aggregate of 5,000,000 shares of Common Stock, and (iv) 5,000,000 Series B-2 common warrants (the “Series B-2 Common Warrants,” and together with the Series B-1 Common Warrants, the “Common Warrants”) exercisable for an aggregate of 5,000,000 shares of Common Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000162828024003067/0001628280-24-003067-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"each purchaser identified on the signature pages thereto"},{"label":"Value","value":"combined purchase price of $1.10"},{"label":"Effective","value":"2024-02-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}